ESTRO 35 2016 S763 ________________________________________________________________________________ put together. The robustness was assessed by applying Hounsfield unit (HU) perturbations of 3.5% and isocenter shifts of 5mm. Single beam optimisation (SBO) using a horizontal beam line was used when possible. PTV constraints were D2% < 107%, D98% > 90% and V95% > 95% (ICRU). Limits to organs-at-risk (OAR) were the dose-surface area for the skin A60Gy (RBE) < 20cm2 [2], maximum dose to the bones DRBE, 2% < 60 Gy (RBE), maximum dose to the nerves and vessels DRBE, 2% < 70 Gy (RBE Results: Patients with field lengths < 18cm (PTV volumes: 164-659 cm3) could be treated with SBO using 2 horizontal beams and table rotation. In the nominal plan, PTVV95% ranged from 96.3-98.9%. SkinA60Gy (RBE) was 10±7.5cm2. Treatment plans were robust against HU perturbations and 5mm shifts in sup-inf and right-left direction with V95 never dropping below 93%. D2% and D98% of the PTV and OAR doses never exceeded the limits. Shifts of 5mm in ant-post direction caused severe underdosage in the PTV down to V95% of 68%. Robust optimisation in ant-post direction could increase these values up to 91%. For larger PTVs (420 cm3-2240cm3) field lengths ranged from 25-34 cm. The length of the field overlapping region essentially influenced the robustness of the treatment plans. Isocenter shifts of 5mm to each other or apart resulted in a PTVD2% change of 7% for an overlap >6cm increasing up to 15% for ≤ 6cm ( Figure 1 ).
Results:
Patients with field lengths < 18cm (PTV volumes: 164-659 cm3) could be treated with SBO using 2 horizontal beams and table rotation. In the nominal plan, PTVV95% ranged from 96.3-98.9%. SkinA60Gy (RBE) was 10±7.5cm2. Treatment plans were robust against HU perturbations and 5mm shifts in sup-inf and right-left direction with V95 never dropping below 93%. D2% and D98% of the PTV and OAR doses never exceeded the limits. Shifts of 5mm in ant-post direction caused severe underdosage in the PTV down to V95% of 68%. Robust optimisation in ant-post direction could increase these values up to 91%. For larger PTVs (420 cm3-2240cm3) field lengths ranged from 25-34 cm. The length of the field overlapping region essentially influenced the robustness of the treatment plans. Isocenter shifts of 5mm to each other or apart resulted in a PTVD2% change of 7% for an overlap >6cm increasing up to 15% for ≤ 6cm (Figure 1 ). Purpose or Objective: During the last couple of years, volumetric modulated arc therapy (VMAT) is a treatment modality of increasing interest in radiation oncology. Thereby VMAT utilizes dynamic gantry rotation, dynamic MLC and varying dose rate. However, in addition the collimator angle could be changed dynamically, thus, increasing the degrees of freedom for the optimization, which might lead to improved dose distributions. This work investigates the feasibility of VMAT optimization including a dynamic collimator rotation.
Conclusion

Material and Methods:
In this work a 20 x 20 x 20 cm^3 homogeneous water phantom with a cigar shaped target volume and a close-by spherical shaped critical structure was used. By means of the Eclipse Research Scripting a predefined collimator rotation was included to a partial arc in a not yet optimized treatment plan. For this purpose a different collimator angle was assigned for each dicom control point. Thereby the collimator rotation takes into account the physical limitations for the dose delivery. This treatment plan was then imported into the treatment planning system Eclipse using the Eclipse Research Scripting interface. Then the VMAT optimization was performed applying the PRO3 optimization algorithm in a research version of Eclipse. For the dose calculation of the optimized treatment plan the Swiss Monte Carlo Plan (SMCP) was used [1] . Similarly, a dose distribution was determined using a static collimator angle as typically applied in conventional VMAT applications. The resulting DVHs for the target and the critical structure were compared for the treatment plans.
Results:
The optimization of a VMAT treatment plan with a dynamically rotating collimator was successfully performed. The comparison of the DVHs for the target volume showed a slight improvement of the coverage as well as the dose homogeneity for the treatment plan using dynamic collimator rotation compared to the plan applying a fixed collimator angle. Additionally, the dose to the critical structure could be reduced when using the dynamic collimator rotation instead of a fixed collimator angle.
Conclusion:
The usage of a dynamic collimator rotation for VMAT is feasible and has the potential to improve the dose distribution for the target while reducing the dose to critical structures. This work was supported by Varian Medical Systems. 
